Ironwood Pharmaceuticals (IRWD) Competitors

Rigel Pharmaceuticals (NASDAQ:RIGL) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.

Which has higher earnings and valuation, RIGL or IRWD?

Rigel Pharmaceuticals has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$203.08M	1.86	-$25.09M	$2.07	10.24
Ironwood Pharmaceuticals	$317.68M	0.37	-$1.00B	-$0.20	-3.61

Do analysts recommend RIGL or IRWD?

Rigel Pharmaceuticals presently has a consensus price target of $36.40, suggesting a potential upside of 71.78%. Ironwood Pharmaceuticals has a consensus price target of $4.78, suggesting a potential upside of 562.79%. Given Ironwood Pharmaceuticals' higher probable upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ironwood Pharmaceuticals	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.13

Which has more volatility and risk, RIGL or IRWD?

Rigel Pharmaceuticals has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

Does the MarketBeat Community believe in RIGL or IRWD?

Ironwood Pharmaceuticals received 48 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.88% of users gave Rigel Pharmaceuticals an outperform vote while only 60.73% of users gave Ironwood Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Rigel Pharmaceuticals	Outperform Votes 467 68.88%	Underperform Votes 211 31.12%
Ironwood Pharmaceuticals	Outperform Votes 515 60.73%	Underperform Votes 333 39.27%

Do institutionals & insiders believe in RIGL or IRWD?

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 9.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 12.7% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media favor RIGL or IRWD?

In the previous week, Rigel Pharmaceuticals had 7 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 1 mentions for Ironwood Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.40 beat Ironwood Pharmaceuticals' score of 0.43 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rigel Pharmaceuticals	Positive
Ironwood Pharmaceuticals	Neutral

Is RIGL or IRWD more profitable?

Rigel Pharmaceuticals has a net margin of 2.46% compared to Ironwood Pharmaceuticals' net margin of -0.65%. Ironwood Pharmaceuticals' return on equity of -0.96% beat Rigel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	2.46%	-14.80%	3.03%
Ironwood Pharmaceuticals	-0.65%	-0.96%	0.74%

Summary

Rigel Pharmaceuticals beats Ironwood Pharmaceuticals on 13 of the 18 factors compared between the two stocks.